ATLANTA -- An investigational quadruple receptor agonist led to a substantial reduction in total body weight with minimal ...

An investigational triple agonist that targets fibroblast growth factor 21, glucagon and GLP-1 receptors cut triglyceride ...

The drug, given as a weekly subcutaneous injection, reduced both triglycerides and liver fat in the phase II trial.

A multicenter team including Endeavor Health and Eli Lilly found that once-weekly eloralintide produced dose-dependent weight ...

Shares of Amgen are up nearly 26% this year and have soared 11% just over the past week.

Eli Lilly (LLY) said on Thursday that eloralintide, its experimental amylin receptor agonist for obesity, helped patients ...

As Pfizer acquires MET-097 maker Metsera, phase 2 data show potential for greater tolerability and once-monthly dosing.

Eli Lilly has linked its amylin agonist eloralintide to up to 20.1% weight loss at Week 48, encouraging the drugmaker to ...

A once-daily oral quadruple receptor agonist induced up to 13.8% weight loss at 13 weeks among adults with overweight or ...

Muna Therapeutics, a clinical stage biotechnology company focused on developing innovative therapeutics for neurodegenerative diseases, today announced that the first subjects have been dosed in a ...

The highest dose of Eli Lilly’s eloralintide led to 20.1% weight loss after 48 weeks in a Phase II trial, exceeding analyst ...